Rigel Pharmaceuticals, Inc.

Symbol: RIGL

NASDAQ

1.02

USD

Market price today

  • -9.0247

    P/E Ratio

  • 4.6026

    PEG Ratio

  • 178.89M

    MRK Cap

  • 0.00%

    DIV Yield

Rigel Pharmaceuticals, Inc. (RIGL) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.93%

Operating Profit Margin

-0.12%

Net Profit Margin

-0.16%

Return on Assets

-0.16%

Return on Equity

0.66%

Return on Capital Employed

-0.28%

Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Mr. Raul R. Rodriguez
Full-time employees:147
City:South San Francisco
Address:1180 Veterans Boulevard
IPO:2000-11-29
CIK:0001034842

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

General Outlook

When we look at how much money they make before expenses, they keep 0.932% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -0.122%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -0.165%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.157% return, is a testament to Rigel Pharmaceuticals, Inc.'s adeptness in optimizing resource deployment. Rigel Pharmaceuticals, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.659%. Furthermore, the proficiency of Rigel Pharmaceuticals, Inc. in capital utilization is underscored by a remarkable -0.276% return on capital employed.

Stock Prices

Rigel Pharmaceuticals, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $1.11, while its low point bottomed out at $1.06. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Rigel Pharmaceuticals, Inc.'s stock market.

Liquidity Ratios

Analyzing RIGL liquidity ratios reveals its financial health of the firm. The current ratio of 126.35% gauges short-term asset coverage for liabilities. The quick ratio (105.28%) assesses immediate liquidity, while the cash ratio (34.94%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio126.35%
Quick Ratio105.28%
Cash Ratio34.94%

Profitability Ratios

RIGL profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -16.45% underscores its earnings before tax deductions. The effective tax rate stands at -7.99%, revealing its tax efficiency. The net income per EBT, 100.00%, and the EBT per EBIT, 134.41%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -12.24%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-16.45%
Effective Tax Rate-7.99%
Net Income per EBT100.00%
EBT per EBIT134.41%
EBIT per Revenue-12.24%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 1.26, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding105
Days of Inventory Outstanding326
Operating Cycle409.11
Days of Payables Outstanding415
Cash Conversion Cycle-6
Receivables Turnover4.37
Payables Turnover0.88
Inventory Turnover1.12
Fixed Asset Turnover141.25
Asset Turnover0.95

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -0.04, and free cash flow per share, -0.04, depict cash generation on a per-share basis. The cash per share value, 0.28, showcases liquidity position. Lastly, the operating cash flow sales ratio, -0.06, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share-0.04
Free Cash Flow per Share-0.04
Cash per Share0.28
Operating Cash Flow Sales Ratio-0.06
Free Cash Flow to Operating Cash Flow Ratio1.04
Cash Flow Coverage Ratio-0.11
Short Term Coverage Ratio-0.43
Capital Expenditure Coverage Ratio-24.75
Dividend Paid and Capex Coverage Ratio-24.75

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 47.74%, highlights its total liabilities relative to assets. With a debt-equity ratio of -1.91, we discern the balance between debt and equity financing. The long-term debt to capitalization, 339.23%, and total debt to capitalization, 210.24%, ratios shed light on its capital structure. An interest coverage of -3.88 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio47.74%
Debt Equity Ratio-1.91
Long Term Debt to Capitalization339.23%
Total Debt to Capitalization210.24%
Interest Coverage-3.88
Cash Flow to Debt Ratio-0.11
Company Equity Multiplier-3.99

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 0.67, provides a glimpse into top-line earnings distributed across each share. Net income per share, -0.14, reflects the portion of profit attributed to each share. The book value per share, -0.16, represents the net asset value distributed per share, while the tangible book value per share, -0.24, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share0.67
Net Income Per Share-0.14
Book Value Per Share-0.16
Tangible Book Value Per Share-0.24
Shareholders Equity Per Share-0.16
Interest Debt Per Share0.39
Capex Per Share-0.09

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -2.79%, indicates top-line expansion, while the gross profit growth, -7.36%, reveals profitability trends. EBIT growth, 62.21%, and operating income growth, 62.21%, offer insights into operational profitability progression. The net income growth, 59.27%, showcases bottom-line expansion, and the EPS growth, 61.11%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth-2.79%
Gross Profit Growth-7.36%
EBIT Growth62.21%
Operating Income Growth62.21%
Net Income Growth59.27%
EPS Growth61.11%
EPS Diluted Growth61.11%
Weighted Average Shares Growth0.93%
Weighted Average Shares Diluted Growth0.93%
Operating Cash Flow Growth92.21%
Free Cash Flow Growth72.05%
10-Year Revenue Growth per Share719.98%
5-Year Revenue Growth per Share142.25%
3-Year Revenue Growth per Share4.35%
10-Year Operating CF Growth per Share96.65%
5-Year Operating CF Growth per Share90.99%
3-Year Operating CF Growth per Share89.33%
10-Year Net Income Growth per Share85.86%
5-Year Net Income Growth per Share67.16%
3-Year Net Income Growth per Share19.94%
10-Year Shareholders Equity Growth per Share-106.90%
5-Year Shareholders Equity Growth per Share-124.05%
3-Year Shareholders Equity Growth per Share-181.64%
Receivables Growth-24.23%
Inventory Growth-39.44%
Asset Growth-12.70%
Book Value per Share Growth-108.42%
Debt Growth45.79%
R&D Expense Growth-59.31%
SGA Expenses Growth-5.97%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 280,117,650, captures the company's total value, considering both debt and equity. Income quality, 0.23, assesses the reliability of reported earnings. The ratio of intangibles to total assets, 11.84%, indicates the value of non-physical assets, and capex to operating cash flow, 261.19%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value280,117,650
Income Quality0.23
Research and Development to Revenue20.98%
Intangibles to Total Assets11.84%
Capex to Operating Cash Flow261.19%
Capex to Revenue-12.83%
Capex to Depreciation-1211.63%
Stock-Based Compensation to Revenue7.53%
Graham Number0.73
Return on Tangible Assets-24.28%
Graham Net Net-0.36
Working Capital45,999,000
Tangible Asset Value-42,522,000
Net Current Asset Value-46,603,000
Invested Capital-2
Average Receivables35,435,000
Average Payables14,825,000
Average Inventory7,320,000
Days Sales Outstanding95
Days Payables Outstanding367
Days of Inventory On Hand283
ROIC-69.97%
ROE0.88%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, -5.64, and the price to book ratio, -5.64, reflect the market's valuation relative to the company's book value. The price to sales ratio, 1.49, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -25.73, and price to operating cash flows, -26.74, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio-5.64
Price to Book Ratio-5.64
Price to Sales Ratio1.49
Price Cash Flow Ratio-26.74
Price Earnings to Growth Ratio4.60
Enterprise Value Multiple-12.13
Price Fair Value-5.64
Price to Operating Cash Flow Ratio-26.74
Price to Free Cash Flows Ratio-25.73
Price to Tangible Book Ratio-8.81
Enterprise Value to Sales2.40
Enterprise Value Over EBITDA-16.50
EV to Operating Cash Flow-48.78
Earnings Yield-9.94%
Free Cash Flow Yield-8.22%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Rigel Pharmaceuticals, Inc. (RIGL) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -9.025 in 2024.

What is the ticker symbol of Rigel Pharmaceuticals, Inc. stock?

The ticker symbol of Rigel Pharmaceuticals, Inc. stock is RIGL.

What is company IPO date?

IPO date of Rigel Pharmaceuticals, Inc. is 2000-11-29.

What is company current share price?

Current share price is 1.020 USD.

What is stock market cap today?

The market cap of stock today is 178885560.000.

What is PEG ratio in 2024?

The current 4.603 is 4.603 in 2024.

What is the number of employees in 2024?

In 2024 the company has 147.